Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
MADRID, Oct. 24, 2013 /PRNewswire/ -- HM Hospitales, a private hospital group in Spain, anticipates treating its first patients with Elekta's Versa HD™ system in 2015. Versa HD, to be sited in the group's sixth hospital, is an advanced radiation treatment system designed to enhance the management of cancer care and treat a broad spectrum of tumors throughout the body. The most sophisticated linear accelerator on the market, Elekta's Versa HD is a single system capable of delivering conventional therapies for an expansive range of indications commonly seen in the clinic, while also permitting treatment of complex cancers that require exceptional targeting accuracy.
"Versa HD will allow us to treat patients with the most modern radiation therapy techniques, from traditional treatments to radiosurgery procedures," says Juan Abarca Cidon, M.D., general manager of HM Hospitales. "We will use Versa HD for virtually all cancer pathologies located throughout the body. The system's High Dose Rate mode and ultra-fast and precise Agility™ beam shaping capabilities also will improve the speed with which we can deliver therapy, which will improve patient comfort through shorter treatment times."
The new medical center, Hospital HM Universitario Puerto del Sur, will be connected to the hospital group's first radiation oncology department – Clara Campal Comprehensive Cancer Center at HM Sanchinarro – via Elekta's MOSAIQ® Oncology Information System (OIS). MOSAIQ replaces the Siemens LANTIS OIS that had been in use at the cancer center.
"The Puerto del Sur clinic will serve an area of approximately one million inhabitants in the area south of Madrid," Dr. Cidon says. "It is important that we provide cancer patients in Mostoles and the wider region with access to the very latest treatment technology."
For more information, visit www.VersaHD.com.
Versa HD is not for sale or distribution in all markets.
For further information, please contact:
Johan Andersson, Director, Investor Relations, Elekta AB
Tel: +46 702 100 451, email: firstname.lastname@example.org
Time zone: CET: Central European Time
Michelle Joiner, Director, Global Public Relations and Brand Management, Elekta
Tel: +1 770-670-2447, email: email@example.com
Time zone: ET: Eastern Time
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives.
Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,500 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker STO:EKTAB. Website: www.elekta.com.
©2012 PR Newswire. All Rights Reserved.